AACR Abstract Submission: Guidelines & Checklist

Q: What is the character limit for an AACR abstract submission?

For the AACR Annual Meeting, the combined length of the abstract body, title, and tables cannot exceed 2,600 characters, excluding spaces and author information. If a table is included, it counts as 800 characters against the limit. For AACR Special Conferences, the body text cannot exceed 3,100 characters including spaces, and tables or figures are not permitted.

Q: Can non-members submit an abstract to AACR?

Non-members may author and present an abstract, but every abstract submitted must be sponsored by an AACR member in good standing. An Active, Emeritus, or Honorary member can sponsor an abstract submitted by a non-member colleague. Alternatively, non-members may apply for AACR membership at least one month prior to the submission deadline to obtain sponsorship privileges.

Q: Can you include tables or figures in an AACR abstract?

Figures are not permitted in any AACR abstract submissions. Tables are permitted only for the AACR Annual Meeting, where each table subtracts 800 characters from the total 2,600-character allowance. Tables are not permitted for AACR Special Conferences.

Q: Are preprints allowed when submitting an abstract to AACR?

Yes, posting a preprint to a public server prior to the abstract submission deadline is acceptable and is not considered a prior publication. However, posting a preprint after the submission deadline and before the abstract is officially published in the AACR online itinerary planner breaches the meeting embargo policy.

Q: What happens if the presenting author cannot attend?

All presenting authors are required to register and attend the conference in person. If an emergency prevents the designated presenter from attending, they must immediately contact the AACR Scientific Programs Department to assign a co-author as the alternate presenter. If no author can attend, the abstract must be formally withdrawn.

Submitting an abstract to an American Association for Cancer Research (AACR) meeting is the premier mechanism for oncology investigators to report original preclinical, translational, and clinical findings. Every AACR abstract submission undergoes competitive peer review by Conference Cochairs and Program Committee members to determine placement in oral minisymposia or poster sessions. Authors must navigate rigorous submission criteria, including strict character budgets, mandatory membership sponsorship, and chemical structure disclosure mandates.

In modern oncology research practice, an abstract is not merely an event application; it represents a formal, citable scientific communication published in an online supplement to the journal Cancer Research. Investigators supported by institutional grants or cancer research funding overview mechanisms must balance competitive disclosure against intellectual property timelines and trial completion. Ensuring adherence to the International Committee of Medical Journal Editors (ICMJE authorship criteria) is equally vital when coordinating multi-center laboratory teams prior to logging into the submission portal.

Purpose of the section

The abstract serves as the standalone summary that determines whether research is accepted for presentation and how it is routed across the AACR scientific program. Conference Cochairs evaluate submissions against three primary criteria: scientific novelty, the significance of the findings to cancer biology or patient care, and overall clarity of presentation. Because reviewers evaluate thousands of submissions within short review windows, an abstract must clearly articulate its underlying scientific question and provide concrete, verifiable data.

Unlike preliminary project proposals or general literature reviews, an AACR abstract must report completed, unpublished findings. Stating that “experiments are ongoing” or that “results will be presented at the meeting” is a primary cause of rejection. The accepted abstract becomes a permanent record of the conference proceedings, establishing priority of discovery while preserving the confidentiality required prior to official meeting presentation.

Structure

Official AACR guidelines mandate that every submitted abstract adhere to a structured four-part architecture. This structure ensures that reviewers can rapidly isolate the study rationale, experimental approach, objective results, and scientific conclusions.

Background and Purpose: An introductory sentence or brief framing that outlines the scientific problem, biological hypothesis, or clinical rationale driving the investigation.
Methods: A succinct description of the experimental systems, patient cohorts, analytical models, assays, or statistical tests utilized to generate the findings.
Results: A direct summary of new, unpublished data. Numerical values, statistical confidence intervals, response rates, or quantitative biological measurements must be explicitly stated.
Conclusions: A definitive statement summarizing what the findings demonstrate and how they advance cancer understanding or translational therapeutic strategies.

How to Submit an AACR Abstract and Track System Limits

When authors prepare to submit an aacr abstract, character accounting is enforced by an automated online submission system. Exceeding character ceilings prevents submission completion. However, character budgets differ between the AACR Annual Meeting and specialized thematic conferences:

Meeting Setting	Maximum Character Ceiling	Space Accounting	Table and Figure Allowances
AACR Annual Meeting	2,600 characters	Spaces excluded from limit; title and body combined	Tables permitted (each table counts as 800 characters); figures excluded
AACR Special Conferences	3,100 characters	Spaces included in limit; body text only	Tables and figures are not permitted
Author and Affiliation Strings	Excluded from limit	Not counted toward body character count	Verified automatically via institutional roster lookups

All abstract submissions must use American English spelling throughout. Authors must define every abbreviation at its first mention in the body text and avoid nonstandard acronyms in the title. Furthermore, only generic drug names are permitted in both the title and body; mentioning proprietary brand names can disqualify the submission from presentation.

A short annotated example

Below is an illustrative, scientifically plausible model abstract demonstrating the four required sections and compliance with character limits and nomenclature rules.

Title: Targeted KRAS G12D Inhibition Overcomes MAPK Reactivation in Preclinical Pancreatic Ductal Adenocarcinoma

[Background and Purpose] Oncogenic KRAS G12D mutations drive tumor progression in pancreatic ductal adenocarcinoma, but single-agent inhibition frequently induces adaptive pathway rebound through ERK reactivation. We investigated whether concurrent targeting of KRAS G12D and receptor tyrosine kinase signaling prevents downstream resistance.

[Methods] Murine KPC-derived organoids and patient-derived xenograft (PDX) models harboring KRAS G12D were treated with the small-molecule inhibitor MRTX1133 alone or in combination with the SHP2 inhibitor SHP099. Tumor proliferation was monitored via flow cytometry and bioluminescent imaging, while Western blotting quantified phosphorylation levels of ERK1/2 and MEK.

[Results] Monotherapy with MRTX1133 reduced organoid viability by 42% at 72 hours, accompanied by rapid ERK phosphorylation recovery within 24 hours. Combination therapy with SHP099 sustained complete MAPK pathway suppression, resulting in an 84% reduction in viable tumor cell counts (p < 0.001). In PDX cohorts (n = 10 per arm), combination treatment led to complete tumor stasis over 28 days without significant animal weight loss, compared to rapid tumor progression in vehicle controls (median survival 19 days vs 48 days, p < 0.0001).

[Conclusions] Dual blockade of KRAS G12D and upstream tyrosine phosphatase signaling prevents compensatory MAPK resurgence and induces durable anti-tumor responses in preclinical pancreatic cancer, supporting clinical trial evaluation.

Annotation: This text contains approximately 1,420 characters (including spaces), sitting comfortably within the 2,600-character Annual Meeting budget and 3,100-character conference ceiling. It uses generic drug designations (MRTX1133, SHP099), defines biological models, and reports concrete quantitative outcomes with statistical markers rather than generalized promises.

Common mistakes

Abstract rejections or administrative exclusions at AACR conferences frequently stem from procedural oversights rather than purely scientific flaws. Authors should guard against the following common pitfalls:

Commercial Trade Names: Using proprietary drug names (e.g., brand-name biologics) instead of generic chemical designations. AACR guidelines mandate generic names; commercial language can trigger disqualification.
Promissory Language Without Data: Submitting statements such as “mechanistic validation will be discussed” or “patient enrollment is currently completing.” Abstracts without tangible data in the Results section are routinely rejected.
Unsponsored Submissions: Failing to secure member sponsorship. Every abstract requires sponsorship by an AACR member in good standing (Active, Emeritus, Honorary, Associate, or Affiliate). Associate members may only sponsor their own presentation if endorsed by an Active, Emeritus, or Honorary member.
Chemical Structure Non-Disclosure: Neglecting chemical disclosure regulations. For research involving low-molecular-weight chemical compounds (< 1500 g/mol per Fall 2025 updates), authors must declare compound utilization upon submission and state their intent to disclose full structures during presentation.
Preprint Embargo Violations: While posting a preprint to a non-commercial server prior to abstract submission is permitted, posting a preprint after the AACR submission deadline breaches the meeting embargo policy.

Checklist

Complete this verification checklist before initiating final submission in the online portal:

Step	Verification Task	Official Requirement
1. Member Sponsorship	Confirm sponsor AACR dues are paid in full for the active calendar year	Active/Emeritus/Honorary (unlimited); Associate (1 as presenter + endorsement); Affiliate (1 as presenter)
2. Character Budget	Measure combined title + body length in plain text editor	≤ 2,600 chars without spaces (Annual Meeting) or ≤ 3,100 chars with spaces (Special Conferences)
3. Structure Validation	Verify all 4 headings are present and populated with empirical data	Background/Purpose, Methods, Results, Conclusions
4. Drug Nomenclature	Scan text for proprietary or commercial trade names	Generic scientific drug names only
5. Chemical Disclosure	Identify low-molecular-weight compounds (< 1500 g/mol)	State compound usage and confirm presentation structure disclosure intent
6. Fee Payment	Submit nonrefundable abstract processing fee	US$85 per abstract submission via credit card or approved payment
7. Presenter Commitment	Confirm presenting author will register for the in-person meeting	Mandatory registration; failure to attend risks abstract withdrawal

Meeting Cycles and the AACR 2026 Abstract Deadline Framework

Navigating the abstract submission timeline requires tracking multiple distinct operational milestones. Regular abstract submissions for the flagship Annual Meeting typically close in mid-November preceding the spring conference. Late-breaking submissions—reserved for high-impact findings that were biologically or clinically unattainable at the regular deadline—close in early January. Similarly, clinical trial placeholder abstracts require final data deposition by late January. Official abstract withdrawal requests must be formally transmitted to AACR scientific staff by early February for regular abstracts, ensuring proceedings supplements remain accurate prior to distribution.

Discipline differences

Abstract submission requirements in oncology diverge sharply from those in general biology or non-clinical disciplines:

Chemical Entity Transparency: Because targeted therapeutics form the core of modern medical oncology, AACR strictly polices chemical identity. Presenters cannot disguise lead compounds under proprietary code names without affirming intent to disclose chemical structures at the podium or poster board.
Clinical Trial Placeholders: Unlike standard basic science abstracts, phase I/II oncology clinical trials often allow placeholder submissions with preliminary design parameters, provided definitive safety and efficacy data are submitted before the late-breaking January deadline.
Encore Trial Allowances: Oncology trialists who have reported preliminary findings at other major symposia may submit encore abstracts for clinical trial sessions, provided the initial presentation venue and date are explicitly documented upon submission.

FAQ

What is the character limit for an AACR abstract submission?